Cosette Pharmaceuticals Announces the Approval and Launch of First Generic Version of RECTIV® (nitroglycerin) ointment, 0.4%, with 180 days Competitive Generic Therapy (CGT) exclusivity
February 22, 2024 08:00 AM Eastern Daylight Time BRIDGEWATER,…
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
January 3, 2024 Only FDA-Approved As-Needed Treatment For The Approximately 6…
Cosette Pharmaceuticals Appoints Ted Smolenski as Vice President of Portfolio & Business Development
Experienced business development executive to accelerate Cosette’s growth…
Apurva Saraf, President and CEO of Cosette Pharmaceuticals, Honored with "CEO of the Year" Award by Avista Capital Partners
Apurva Saraf, President and CEO of Cosette Pharmaceuticals, Honored with…
Cosette Pharmaceuticals Partners With Mark Cuban Cost Plus Drug Company to Make CLOMID® More Affordable
Online Pharmacy to Offer Proven Fertility Medication at Low Cost BRIDGEWATER,…
Cosette Pharmaceuticals Launches Metronidazole Vaginal Gel 0.75%, AB-rated to MetroGel-Vaginal® 0.75%
Further expands Cosette’s portfolio in affordable women’s healthcare…
EY Announces Apurva Saraf, President and CEO of Cosette Pharmaceuticals as an Entrepreneur Of The Year® 2023 New Jersey Award Winner
Bridgewater, June 14, 2023 – Ernst & Young LLP (EY US) today announced that…
Cosette Pharmaceuticals Acquires Intrarosa® from Endoceutics, Inc.
Acquisition accelerates Cosette’s women’s health portfolio; with a…
Jackie Beltrani Joins Cosette Pharmaceuticals as Director, Commercial Operations.
We are pleased to announce that Jackie Beltrani has joined Cosette…
Cosette Pharmaceuticals Launches Betaine Anhydrous Powder, AB-rated to Cystadane® (betaine anhydrous for oral solution)
Launch offers important and affordable alternative for patients Bridgewater,…